Physician profile
Michael G Gates
NPI 1801054754
$2,560.77
in general payments reported to CMS, 2019-2025
20 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $62.56 · 2021: $331 · 2022: $652 · 2023: $888 · 2024: $62.39 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $849.47 | 2019-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $651.44 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $206.03 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $145.90 | 2025 | |
| Csl Behring | $119.99 | 2022-2023 | Haegarda |
| Abbvie INC. | $82.28 | 2022 | |
| Sunovion Pharmaceuticals INC. | $66.53 | 2019-2020 | |
| Organon LLC | $59.24 | 2025 | Vtama |
| Pfizer INC. | $54.46 | 2022-2024 | |
| Genzyme Corporation | $48.85 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $45.73 | 2022-2023 | Uptravi, Opsumit |
| Genentech USA, INC. | $41.53 | 2022 | |
| Pulmonx Corporation | $38.34 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Grifols USA, LLC | $37.65 | 2023 | Xembify |
| Glaukos Corporation | $25.32 | 2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Iaccess Precision Blade |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $24.06 | 2023 | Xywav |
| Pharming Healthcare, INC. | $17.54 | 2019 | |
| Electromed, INC. | $16.87 | 2019 | |
| Amgen INC. | $16.06 | 2022 | |
| Kaleo, INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.